Pulse Biosciences stock faces Oppenheimer meeting after 3.87 percent fall

Published on 10/04/2026 at 20:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pulse Biosciences stock heads toward an October 7 management meeting in San Francisco. Second-quarter revenue reached USD 434,000, while adjusted loss missed consensus.

PLSE, US74587B1017, Illustration mit AI erstellt.

Pulse Biosciences stock (ISIN US74587B1017) closed at USD 47.90 on Nasdaq on October 2, 2026, down 3.87 percent from the prior close. The next scheduled corporate checkpoint is a management meeting with Oppenheimer in San Francisco on October 7, 2026, according to Markets Insider.

Oppenheimer meeting sets next checkpoint

The event is scheduled for October 7 and October 8 and is hosted by Oppenheimer. The meeting gives investors a near-term date for management commentary on the companys clinical programs and commercialization plans, while the stock remains 18.7 percent below its 52-week high of USD 58.90.

Pulse Biosciences is developing medical devices based on Nano-Pulse Stimulation technology. Its CellFX System is designed for dermatologic applications, while newer nPulse systems target soft-tissue and cardiac procedures, according to the companys investor-relations profile at Pulse Biosciences.

Q2 revenue remains small

For the second quarter of 2026, Pulse Biosciences reported revenue of USD 434,000 and an adjusted loss of USD 0.36 per share. MarketBeat said the loss exceeded the USD 0.29 consensus estimate, while revenue trailed the USD 0.53 million estimate.

The comparison highlights the gap between the companys development ambitions and its current commercial base. Pulse Biosciences also reported USD 101.62 million in cash at June 30, 2026, giving the Oppenheimer meeting a financial angle alongside the clinical milestones.

Analyst target sits above the stock

MarketBeat reported a Moderate Buy consensus from seven analysts and an average price target of USD 50.20. That target lies 4.8 percent above the October 2 price, while recent published targets included USD 58 from Needham and USD 70 from BTIG.

The main counter-factor is execution. Early clinical data must translate into regulatory progress, physician adoption and recurring product revenue before the companys valuation can be supported by operating results.

Pulse Biosciences stock ends below its high

Pulse Biosciences stock closed at USD 47.90 on Nasdaq on October 2, 2026, with volume of 519,092 shares and a market capitalization of USD 3.4 billion.